BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

SN Bioscience Secures US FDA Orphan Drug Designation For SNB 101 In Gastric Cancer

SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (incl...

December 25, 2025 | News

CHITOSE And FUJIFILM Biosciences Form Strategic Alliance To Advance Biopharmaceutical Manufacturing

Collaboration formed to accelerate biopharmaceutical manufacturing combining high performing CHO-MK cells and GMP-manufactured culture media. Ch...

December 22, 2025 | News

GenSci, RTW And Yarrow Forge US Focused Biotech Partnership To Advance First In Class Thyroid Autoimmune Therapy

Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients impacted by autoimmune and endocrinology di...

December 17, 2025 | News

Akeso Secures FDA Clearance to Launch Global Phase III Gastric Cancer Trial of Cadonilimab

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in ...

December 15, 2025 | News

Mango Sciences Partners with ImmunoACT to Expand Access to NexCAR19 CAR-T Therapy in India

Mango Sciences, Inc., the Boston, US, and Bengaluru, IN-based data and AI company, announced a strategic partnership with ImmunoAdoptive Cell Therapy (Immu...

December 08, 2025 | News

Biocytogen Announces FDA IND Clearance for IDE034 Bispecific B7H3 PTK7 ADC Licensed to IDEAYA Biosciences

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision o...

December 08, 2025 | News

Neurimmune And Alexion Expand Global Collaboration To Advance NI009 For Light Chain Amyloidosis

Neurimmune announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca Rare Disease ...

December 05, 2025 | News

Imugene and JW Therapeutics Launch First-in-Class “Mark and Kill” Solid Tumor Collaboration

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytic...

December 01, 2025 | News

BioDlink Drives Global Biologics Innovation with World’s First Approved EGFR-Targeted ADC

Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyng...

December 01, 2025 | News

Mabwell Doses First Patient in Phase One Two Study of Novel CDH17 Targeting ADC 7MW4911 for Advanced Solid Tumours

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed...

November 26, 2025 | News

Harbour BioMed Deepens Global Collaboration with AstraZeneca to Advance Next Generation Biotherapeutics

Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...

November 25, 2025 | News

China Marks a Landmark Moment as BioDlink and Lepu Biopharma Launch the World’s First EGFR Targeting ADC

Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their par...

November 24, 2025 | News

Vaxcellbio’s CSO Outlines How DDS Enabled Nanobodies Could Redefine Global Treatment Pathways

Vaxcellbio is betting on the combined power of nanobodies and advanced drug delivery science to push boundaries across ophthalmology and other chronic dise...

November 20, 2025 | Interaction

Akeso Initiates First-in-Human Trial of Personalised mRNA Vaccine AK154 for Pancreatic Cancer

Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vacc...

November 11, 2025 | News

Stay Connected